Proportion patients in sustained disease remission 1 year [clinicaltrials_resource:4572fd866587b224b91cad8e5d5f58fb]
To evaluate the potential clinical benefit of hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice in patients with Crohn' s disease.
clinicaltrials_vocabulary:other outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:other-outcome]
Proportion patients in sustained disease remission 1 year [clinicaltrials_resource:4572fd866587b224b91cad8e5d5f58fb]
To evaluate the potential clinical benefit of hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice in patients with Crohn' s disease.
Bio2RDF identifier
4572fd866587b224b91cad8e5d5f58fb
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4572fd866587b224b91cad8e5d5f58fb
measure [clinicaltrials_vocabulary:measure]
Proportion patients in sustained disease remission
time frame [clinicaltrials_vocabulary:time-frame]
description
To evaluate the potential clin ...... atients with Crohn' s disease.
identifier
clinicaltrials_resource:4572fd866587b224b91cad8e5d5f58fb
title
Proportion patients in sustained disease remission 1 year
@en
type
label
Proportion patients in sustain ...... 2fd866587b224b91cad8e5d5f58fb]
@en